Translarna AdCom Has DMD Experience, But Most Opposed Approval Of Prior Applications

 
• By Derrick Gingery
  
FDA Advisory Committee Feature image
Advisory committee members will review another proposed Duchenne muscular dystrophy drug on Sept. 28.

More from US FDA Performance Tracker

More from Regulatory Trackers